Blueprint Medicines Corp (NASDAQ:BPMC) has been assigned an average recommendation of “Buy” from the ten research firms that are covering the company, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $105.83.
Several research firms have issued reports on BPMC. ValuEngine raised shares of Blueprint Medicines from a “buy” rating to a “strong-buy” rating in a research report on Friday, May 10th. Morgan Stanley began coverage on shares of Blueprint Medicines in a research report on Wednesday, April 3rd. They set an “overweight” rating and a $112.00 price target on the stock. BidaskClub raised shares of Blueprint Medicines from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 5th. Goldman Sachs Group reissued a “buy” rating and issued a $125.00 price objective on shares of Blueprint Medicines in a research report on Thursday. Finally, Wedbush reissued an “outperform” rating on shares of Blueprint Medicines in a research report on Tuesday, February 26th.
NASDAQ BPMC opened at $84.68 on Monday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 6.59 and a current ratio of 6.59. Blueprint Medicines has a 1 year low of $44.58 and a 1 year high of $89.00. The firm has a market cap of $4.14 billion, a price-to-earnings ratio of -15.71 and a beta of 1.53.
Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($1.98) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.83) by ($0.15). Blueprint Medicines had a negative return on equity of 59.26% and a negative net margin of 603.88%. The firm had revenue of $0.73 million for the quarter, compared to the consensus estimate of $1.38 million. During the same period last year, the company posted ($1.29) earnings per share. The business’s revenue was down 23.2% compared to the same quarter last year. Equities research analysts anticipate that Blueprint Medicines will post -7.76 EPS for the current year.
In other news, insider Ariel Hurley sold 415 shares of the stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $85.55, for a total value of $35,503.25. Following the transaction, the insider now directly owns 415 shares of the company’s stock, valued at $35,503.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jeffrey W. Albers sold 20,000 shares of the stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $86.39, for a total transaction of $1,727,800.00. Following the completion of the transaction, the chief executive officer now directly owns 48,961 shares in the company, valued at $4,229,740.79. The disclosure for this sale can be found here. Insiders sold 44,359 shares of company stock worth $3,798,843 over the last three months. Insiders own 3.15% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Advisor Group Inc. grew its stake in shares of Blueprint Medicines by 101.6% in the first quarter. Advisor Group Inc. now owns 379 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 191 shares in the last quarter. NumerixS Investment Technologies Inc acquired a new position in shares of Blueprint Medicines in the first quarter valued at about $30,000. US Bancorp DE grew its stake in Blueprint Medicines by 42.7% during the first quarter. US Bancorp DE now owns 668 shares of the biotechnology company’s stock worth $53,000 after buying an additional 200 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. grew its stake in Blueprint Medicines by 518.3% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 674 shares of the biotechnology company’s stock worth $54,000 after buying an additional 565 shares in the last quarter. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC grew its stake in Blueprint Medicines by 24.2% during the fourth quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,000 shares of the biotechnology company’s stock worth $107,000 after buying an additional 390 shares in the last quarter. Institutional investors and hedge funds own 97.46% of the company’s stock.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Read More: Bear Market – How and Why They Occur
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.